1. Home
  2. CRSP vs GNW Comparison

CRSP vs GNW Comparison

Compare CRSP & GNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • GNW
  • Stock Information
  • Founded
  • CRSP 2013
  • GNW 1871
  • Country
  • CRSP Switzerland
  • GNW United States
  • Employees
  • CRSP 393
  • GNW N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • GNW Life Insurance
  • Sector
  • CRSP Health Care
  • GNW Finance
  • Exchange
  • CRSP Nasdaq
  • GNW Nasdaq
  • Market Cap
  • CRSP 3.3B
  • GNW 2.9B
  • IPO Year
  • CRSP 2016
  • GNW 2004
  • Fundamental
  • Price
  • CRSP $35.62
  • GNW $7.05
  • Analyst Decision
  • CRSP Buy
  • GNW
  • Analyst Count
  • CRSP 17
  • GNW 0
  • Target Price
  • CRSP $74.53
  • GNW N/A
  • AVG Volume (30 Days)
  • CRSP 2.0M
  • GNW 6.9M
  • Earning Date
  • CRSP 05-06-2025
  • GNW 04-30-2025
  • Dividend Yield
  • CRSP N/A
  • GNW N/A
  • EPS Growth
  • CRSP N/A
  • GNW 141.92
  • EPS
  • CRSP N/A
  • GNW 0.49
  • Revenue
  • CRSP $37,675,000.00
  • GNW $7,217,000,000.00
  • Revenue This Year
  • CRSP $51.35
  • GNW N/A
  • Revenue Next Year
  • CRSP $282.16
  • GNW N/A
  • P/E Ratio
  • CRSP N/A
  • GNW $14.23
  • Revenue Growth
  • CRSP N/A
  • GNW N/A
  • 52 Week Low
  • CRSP $30.04
  • GNW $5.87
  • 52 Week High
  • CRSP $67.88
  • GNW $7.90
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.74
  • GNW 58.45
  • Support Level
  • CRSP $33.03
  • GNW $6.81
  • Resistance Level
  • CRSP $39.38
  • GNW $7.11
  • Average True Range (ATR)
  • CRSP 1.81
  • GNW 0.18
  • MACD
  • CRSP -0.19
  • GNW 0.04
  • Stochastic Oscillator
  • CRSP 33.64
  • GNW 91.04

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About GNW Genworth Financial Inc

Genworth Financial is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. most of the revenue is generated by the Long-Term Care Insurance segment. The company earns most of its revenue in the United States.

Share on Social Networks: